ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
MWN-AI** Summary
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company, has made significant progress in its Phase IIa clinical trial of ONP-002, an innovative intranasal neurosteroid aimed at treating acute concussion and mild traumatic brain injury (mTBI). The company recently announced the completion of its first site initiation visit (SIV) at a trial location in Australia, which marks the formal start of clinical operations at this site. This visit included extensive training for site staff, protocol orientation, and the completion of necessary regulatory documentation. Two additional trial sites are currently undergoing final reviews by their Research Governance Offices (RGO) following prior approvals from a Human Research Ethics Committee (HREC). Once these reviews are finalized, all three sites will be ready to commence patient enrollment and dosing.
The Phase IIa trial is designed as a randomized, placebo-controlled study, targeting the enrollment of 40 patients across the three sites, and aims to assess the safety, tolerability, and preliminary clinical effects of ONP-002 when administered within 12 hours of concussion onset. The primary endpoints include monitoring adverse events, conducting neurocognitive assessments, and evaluating participant compliance.
ONP-002 represents a novel approach to concussion treatment, focusing on mitigating the neuroinflammatory response associated with brain injuries rather than merely managing symptoms. Following promising results from Phase 1 trials—where it was found to be safe and well-tolerated—this Phase IIa trial reflects Oragenics’ commitment to advancing therapies for conditions currently lacking effective pharmacological solutions. The successful activation of trial sites represents a critical step toward addressing the healthcare needs of millions affected by these injuries globally.
MWN-AI** Analysis
Oragenics, Inc. (NYSE American: OGEN) has recently announced the completion of the first site initiation visit for its Phase IIa clinical trial of ONP-002, marking an important milestone in its development of innovative therapeutics for concussion and mild traumatic brain injury (mTBI). The company’s proprietary intranasal delivery technology positions it at the forefront of a market that is rapidly evolving in response to the growing recognition of brain injuries.
As Oragenics prepares to commence patient enrollment at its sites in Australia, several factors should be considered by investors evaluating the company’s potential. Firstly, the completion of the first site initiation visit signifies effective operational execution, which enhances investor confidence in management’s ability to navigate the complexities of clinical trials. Given that there are currently no FDA-approved pharmacological treatments for concussion or mTBI, the success of ONP-002 could fill a significant unmet need in the healthcare market, which addresses a potential customer base of approximately 69 million people annually.
The company’s commitment to safety and efficacy, demonstrated in earlier Phase I trials with zero serious adverse events, further supports the potential for ONP-002 to capture market attention. Positive preliminary outcomes from the ongoing Phase IIa trial could lead to increased investor interest and possibly substantial stock price appreciation.
However, investors should also remain cognizant of the inherent risks associated with clinical-stage biotechnology companies. The reliance on the successful completion of regulatory processes and eventual market acceptance poses uncertainties that may impact stock performance.
In summary, Oragenics represents a speculative but potentially rewarding investment opportunity for those willing to accept the associated risks. Active monitoring of trial results and developments will be crucial as the company transitions from research to product development stages. Positioning oneself now could yield significant long-term returns should ONP-002 meet its clinical objectives.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA
SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial operations at the first of three planned trial sites in Australia, including completion of site staff training, protocol orientation, and site regulatory documentation.
The remaining two clinical trial sites are currently completing their Research Governance Office (RGO) reviews — the final administrative step required following Human Research Ethics Committee (HREC) approval before each site can activate to begin patient enrollment and dosing. The Company expects these reviews to be completed in the near term, at which point all three sites will be positioned to enroll patients.
The Phase IIa trial initiation follows the Company's receipt of HREC approval earlier this year, which represented the final regulatory clearance required to commence clinical site contract finalization, activation, and onboarding.
PHASE IIA CLINICAL TRIAL OVERVIEW
The Phase IIa trial is a randomized, placebo-controlled study evaluating the safety, tolerability, and preliminary clinical signals of ONP-002 in patients presenting with acute concussion and mild traumatic brain injury. Key design parameters include:
- Enrollment target: 40 patients across three Australian clinical sites
- Dosing window: First dose administered within 12 hours of concussion onset
- Primary endpoints: Safety (adverse events, nasal examinations), neurocognitive follow-up assessments, and participant compliance/tolerability
- Trial status: First SIV complete; two remaining sites in RGO final review prior to activation
"We said we would advance ONP-002 into patients in Australia — and that process is now underway. Our first site is trained, operational, and ready to enroll. The remaining sites are completing their final governance reviews, and we expect them to follow shortly. This is the kind of measured, disciplined execution that clinical development demands, and our team is delivering. Patient dosing is the next step, and we are ready." — Chief Executive Officer, Janet Huffman.
"Site initiation marks the transition from regulatory preparation to active clinical operations. Our investigators are trained on the protocol, safety procedures are in place, and our CRO is coordinating operations across all three sites. The RGO review process at the remaining sites is proceeding as expected. We anticipate completing site activation across all three locations in the near term and beginning patient enrollment shortly thereafter."
— Chief Medical Officer, Dr James Kelly M.D.
ABOUT ONP-002
ONP-002 is a first-in-class intranasal neurosteroid in Phase IIa clinical development for the treatment of concussion and mild traumatic brain injury. Unlike current approaches limited to symptom management and rest, ONP-002 is designed to interrupt the neuroinflammatory cascade triggered by brain trauma — reducing neuroinflammation, oxidative stress, and cerebral edema at the source. Phase 1 clinical trials in 40 patients demonstrated ONP-002 was safe and well-tolerated across all dose levels with zero serious adverse events (SAEs). There are currently no FDA-approved pharmacological treatments for concussion or mTBI.
FORWARD-LOOKING STATEMENTS
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our product candidates, including without limitation ONP-002 and our proprietary nasal device; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials for our product candidates, including ONP-002 for the treatment of concussion and mTBI; our acquisition strategy and prospects; and our ability to finance our operations. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project," "potential," "may," "will," "could," "should," and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our most recent Form 10-K, Form 10-Q and other filings we make with the U.S. Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. All information we set forth in this press release is as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
ABOUT ORAGENICS
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal drug delivery technology. The Company's lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa clinical development for the treatment of concussion and mild traumatic brain injury (mTBI) — conditions affecting an estimated 69 million people globally each year with no approved pharmacological treatment. Oragenics’ intranasal delivery platform is designed to enable rapid, non-invasive delivery of therapeutics directly to the brain by bypassing the blood-brain barrier. The Company is exploring broadening its CNS pipeline strategy through both internal development and strategic business development. For more information, visit www.Oragenics.com.
Investor Contact:
800-383-4880
ir@oragenics.com
FAQ**
What specific criteria did Oragenics Inc. OGEN use to select the Australian sites for the Phase IIa clinical trial of ONP-002, and how do these sites align with the trial's objectives?
Can Oragenics Inc. OGEN elaborate on the expected timeline for completing the RGO reviews at the remaining clinical trial sites and the subsequent patient enrollment process?
What safety measures and monitoring protocols has Oragenics Inc. OGEN established to ensure patient safety during the Phase IIa trial of ONP-002?
How does Oragenics Inc. OGEN plan to leverage the findings from this Phase IIa trial to further its pipeline of brain-targeted therapeutics in the future?
**MWN-AI FAQ is based on asking OpenAI questions about Oragenics Inc. (NYSE: OGEN).
NASDAQ: OGEN
OGEN Trading
-10.51% G/L:
$0.877 Last:
324,728 Volume:
$0.99 Open:
